SCHEMBL2853876

SCHEMBL2853876

COc1ccc(C(=O)O)cc1Oc1ccc2nc(NC(=O)C3CC3)sc2n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.51
RAB9A P51151 4/20 0.51
HSP90AA1 P07900 1/20 0.51
BRAF P15056 2/20 0.51
ALDH1A1 P00352 3/20 0.50
MAPT P10636 2/20 0.50
TSHR P16473 1/20 0.50
HSD17B10 Q99714 1/20 0.50
KDR P35968 3/20 0.48
PDGFRB P09619 1/20 0.48
KIT P10721 1/20 0.48
FLT1 P17948 1/20 0.48
MAP4K1 Q92918 1/20 0.44
KDM4E B2RXH2 3/20 0.43
HTT P42858 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
RXFP1 Q9HBX9 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2856533 0.92 NPC1 (0.61) NPC1RAB9AHSP90AA1BRAFALDH1A1
SCHEMBL23797943 0.89 KDR (0.55) NPC1RAB9AHSP90AA1BRAFALDH1A1
SCHEMBL2859325 0.88 KDR (0.53) NPC1RAB9AHSP90AA1BRAFALDH1A1
SCHEMBL2857653 0.87 BRAF (0.51) NPC1RAB9AHSP90AA1BRAFALDH1A1
SCHEMBL3512224 0.84 BRAF (0.51) NPC1RAB9AHSP90AA1BRAFALDH1A1
SCHEMBL23797948 0.83 NPC1 (0.61) NPC1RAB9AHSP90AA1BRAFALDH1A1
SCHEMBL2861512 0.82 KDR (0.52) BRAFKDRPDGFRBKITFLT1
SCHEMBL4288809 0.81 KDR (0.61) NPC1RAB9AHSP90AA1BRAFKDR
SCHEMBL2853863 0.79 KDR (0.52) NPC1RAB9ABRAFALDH1A1MAPT
SCHEMBL2860036 0.79 BRAF (0.51) BRAFKDRPDGFRBKITFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2184285-B1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-11-04 EP disclosed
US-8344135-B2 Heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-01-01 US disclosed
US-20100249119-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-30 US disclosed
EP-2184285-A1 HETEROCYCLIC COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-05-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249119-A1 HETEROCYCLIC COMPOUND AND USE THEREOF BRAF, NRAS, RAF1 NPC1 3266/4885RAB9A 383/4885HSP90AA1 1439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.